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aBstraCt
BaCkground: In this study, we aimed to measure neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte 
ratio (PLR) and mean platelet volume (MPV) levels in primary acquired nasolacrimal duct obstruction (PANDO) 
patients and to determine whether there it could be used as a marker for PANDO. 
Material and Methods: This retrospective study included 61 patients with PANDO and 65 healthy controls. 
Data were excluded from the file records of patients who underwent external dacryocystorhinostomy (DCR). Blood 
samples were obtained from venous blood and serum neutrophil, lymphocyte, and platelet data of all patients were 
recorded and also, NLR-PLR values were calculated.
results: There was no significant difference between PANDOs and controls in terms of gender and age (p > 0.05). 
Neutrophil-to-lymphocyte was significantly increased in PANDOs compared to the controls (p < 0.05). There was 
no statistically significant difference between PANDOs and controls in term of PLR (p > 0.05). The average MPV 
in the PANDOs was found to be significantly lower than controls (p < 0.05)
ConClusion: Neutrophil-to-lymphocyte ratio and MPV counts were associated with PANDO.
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nasolacrimal duct obstruction
Ophthalmol J 2020; Vol. 5, 76–80
introduCtion
Epiphora develops after obstruction of nasol-
acrimal canal and this condition is common in so-
ciety. Acquired nasolacrimal duct obstructions are 
divided into two; primary and secondary. Primary 
acquired nasolacrimal duct obstruction (PANDO) 
is the most common type and especially seems after 
the age of 50 years. Primary acquired nasolacrimal 
duct obstruction is known to be more common in 
women than men (3-fold) [1]. Pathological stud-
ies showed that PANDO develops as a result of 
fibrous obstruction secondary to chronic inflamma-
tion [2–4].
Neutrophil-to-lymphocyte ratio (NLR) and 
platelet-to-lymphocyte ratio (PLR), calculated 
from hemogram are systemic inflammatory re-
sponses. Many different studies published before 
have shown that NLR and PLR are indicative of 
systemic inflammation [5–10].
Mean platelet volume (MPV) is a parameter that 
indicates the status of platelets, and MPV is associ-
ated with inflammation [11].
According to our literature review, there are dif-
ferent studies researched the association between 
NLR, MPV, PLR and many diseases but, there was 
no study to measure/examine NLR, MPV, PLR lev-
els in PANDO disease. In this study, we purposed 
to measure NLR, PLR and MPV levels in PANDO 
patients and to determine whether there is a signifi-
cant change.
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Material and Methods
This retrospective case-control study was con-
ducted at Sakarya University Training and Research 
Hospital, Ophthalmology Clinic between January 
and November 2019. Data were excluded from 
the file records of patients who underwent external 
dacryocystorhinostomy (DCR) between January 
2017 and November 2018. Our study was carried 
out according to the ethical principles set out in the 
Helsinki Declaration and the consent was obtained 
from Sakarya University Medical School Ethics 
Committee. The study included 61 patients with 
PANDO and 65 healthy controls. Healthy control 
patients consisted of persons with senile cataract or 
refractive error in ophthalmology outpatient clinic. 
Age and sex-matched in two groups.
Criteria for inclusion were: patients with PAN-
DO and operated by standard external DCR tech-
nique. Criteria for exclusion were: traumatic etiol-
ogy, cancer history, systemic diseases (such as car-
diovascular diseases and diabetes), history of cere-
brovascular disease, blood diseases, acute/chronic 
kidney failure.
Hemogram parameters of all cases were mea-
sured by Cell-DYN 3700 (Cell-DYN 3700, Ab-
bott Diagnostics, Abbott Park, IL, USA) automated 
hematology analyzer. According to the results of 
hemogram; neutrophil, lymphocyte, MPV and 
platelet counts of all the cases were recorded and 
NLR-PLR values were calculated.
statistiCal analysis
Data analyzed due to the SPSS software (version 
17.0, SPSS Inc., Chicago, IL, USA) program. Data 
were also reported as mean and standard deviation 
(± SD). Comparison of the independent groups 
was done by parametric Student t-test. The cut-off 
point between PANDOs and controls determined 
due to receiver operating characteristic (ROC) curve 
analysis. According to the cut-off value, sensitivity 
and specificity values were calculated. P < 0.05 was 
considered significant.
results
Our study consisted of a total of 126 people, 
including 61 patients with PANDO and 65 healthy 
controls. The gender distribution of patients in 
PANDOs and controls was 17 male/44 female and 
23 male/42 female, respectively. The mean age of 
the PANDOs was 53.21 ± 14.23 years and the 
controls were 55.29 ± 8.60 years. Primary acquired 
nasolacrimal duct obstruction group and controls 
were similar in terms of gender, age, and systemic 
diseases (diabetes, hypertension) (p > 0.05) (Tab. 1).
The mean WBC count was 7.44 ± 2.07 109/L 
in the PANDOs and 7.28 ± 2.18 109/L in the 
controls and the difference between the groups was 
not significant (p = 0.678). The mean neutrophil 
count was 4.34 ± 1.60 109/L in the PANDOs and 
3.94 ± 1.44 109/L in the controls and the difference 
between the groups was not significant (p = 0.146). 
The mean lymphocyte count was 2.34 ± 0.74 109/L 
in the PANDOs and 2.54 ± 1.05 109/L in the con-
trols and the difference between the groups was not 
significant (p = 0.232).
The mean platelet count was 245.72 ± 57.04 109/L 
in the PANDOs and 246.27 ± 56.42 109/L in the 
controls and the difference between the groups was 
not significant (p = 0.956). The mean NLR was 
1.99 ± 0.89 in the PANDOs and 1.69 ± 0.66 in 
the controls. NLR was significantly higher in the 
PANDOs than in the controls (p = 0.032). The 
mean PLR was 112.74 ± 35.93 in the PANDOs and 
108.77 ± 40.05 in the controls and the difference 
between the groups was not significant (p = 0.560). 
The mean MPV was 8.00 ± 1.55 fL in the PANDOs 
and 9.01 ± 1.77 fL in the controls. MPV was signifi-
table 1. demographic features in the primary acquired nasolacrimal duct obstruction (pando) and control groups
pando 
(n = 61)
Control 
(n = 65)
p*
age (years) 53.21 ± 14.23 55.29 ± 8.60 0.320
Sex 0.369
Male 17 23
Female 44 42
DM 6 10 0.354
HT 7 10 0.525
DM — diabetes mellitus; HT — hypertension; *independent samples t-test
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cantly decreased in the PANDOs than the controls 
(p = 0.001) (Tab. 2).
In the ROC analysis, area under curve (AUC) 
for NLR was 0.597, the cut-off value was 1.77, the 
sensitivity was 57%, and the specificity was 62% 
(95% CI: 0.498–0.696). The area under curve for 
PLR was 0.536, the cut-off value was 107.99, the 
sensitivity was 55%, and the specificity was 53% 
(95% CI: 0.434–0.637). The AUC for MPV was 
0.735, the cut-off value was 8.22, the sensitivity 
was 70%, and the specificity was 72% (95% CI: 
0,645–0,824) (Tab. 3).
disCussion
According to studies in the literature, this is the 
first study investigating the relationship between 
NLR, PLR, MPV and PANDO. The present study 
showed us that NLR and MPV were associated with 
PANDO; however, the relationship between PLR 
and PANDO was not seen in this study. 
Primary acquired nasolacrimal duct obstruction 
is the main cause of nasolacrimal duct obstruction 
in adult humans. Previous studies have shown that 
PANDO develops secondary to chronic inflamma-
tion [2–4]. In addition, some studies in different 
diseases indicate that NLR, PLR and MPV can be 
used to predict inflammation [5, 7–11].
The neutrophil-lymphocyte ratio is considered 
an easy and practical indicator of systemic inflam-
mation. Some studies have shown that NLR can be 
used as a prognostic indicator in coronary artery 
disease, Behçet’s disease, rheumatoid arthritis and 
some malignancies [5, 12–16]. Systemic inflam-
mation typically involves lymphopenia and neu-
trophilia [17]. Alan et al. reported that the NLR lev-
els was increased in patients with Behçet’s syndrome 
than controls [15]. In our study, NLR was signifi-
cantly increased in PANDOs compared to control 
patients, and we think this might be used to predict 
the development of nasolacrimal duct obstruction.
The PLR is cheap, and giving some information 
about condition of platelets and white cells. Plate-
let-to-lymphocyte ratio is a predictor that has been 
studied in recent years and has shown the system-
atic inflammation (presence and severity) [18]. The 
relationship between PLR and various cancer types 
and acute coronary syndrome has been reported 
in previous [19, 20]. There are studies reporting 
that PLR is a negative prognostic factor in some 
inflammatory conditions [21, 22] Azab et al. re-
ported a relationship between increased PLR and 
long-term mortality in patients with myocardial 
infarction [10]. In another study, it was found that 
elevation in PLR was associated with non-dipper 
status in hypertensive patients [23]. In our study, 
table 2. laboratory findings in the primary acquired nasolacrimal duct obstruction (pando) and control groups
pando 
(n = 61)
Control 
(n = 65)
p*
WBC [109/l] 7.44 ± 2.07 7.28 ± 2.18 0.678
Neutrophil [109/l] 4.34 ± 1.60 3.94 ± 1.44 0.146
lymphocyte [109/l] 2.34 ± 0.74 2.54 ± 1.05 0.232
platelet [109/l] 245.72 ± 57.04 246.27 ± 56.42 0.956
Nlr 1.99 ± 0.89 1.69 ± 0.66 0.032
plr 112.74 ± 35.93 108.77 ± 40.05 0.560
MpV [fl] 8.00 ± 1.55 9.01 ± 1.77 0.001
WBC — white blood cell; Nlr — neutrophil-to-lymphocyte ratio; plr — platelet-to-lymphocyte ratio; MpV — mean platelet volume; *independent samples t test
table 3. receiver operating characteristic (roC) curve analyses of neutrophil-to-lymphocyte ratio (nlr), 
platelet-to-lymphocyte ratio (plr) and mean platelet volume (MpV) in primary acquired nasolacrimal duct obstruction 
(pando)
auC Cut off sensitivity specificity
Nlr 0.597 1.77 0.57 0.62
plr 0.536 107.99 0.55 0.53
MpV 0.735 8.22 0.70 0.72
aUC — area under curve
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there was no increase or decrease in PLR levels in 
the patient group because there was no signifi-
cant change in platelet and lymphocyte counts in 
both groups.
Mean platelet volume is being used as a new 
indicator of inflammation. Inagaki et al. found that 
MPV levels were significantly decreased in the ad-
vanced non-small cell lung cancer group than the 
controls [24]. In addition, Kisacik et al. showed that 
MPV was significantly decreased in patients with 
ankylosing spondylitis and rheumatoid arthritis as 
compared to controls [25]. In our study, we found 
that in MPV levels were significantly decreased in 
PANDOs than the controls. The best-known ef-
fects of inflammatory disorders on hematopoiesis 
are anemia and thrombocytosis [26, 27]. It has been 
demonstrated in previous studies that MPV reflects 
platelet activation [28–31]. These studies suggest 
that there is a relationship between inflammatory 
diseases and MPV. In our study, we can link the 
statistically significant low occurrence of MPV to 
this mechanism.
The limitations of the study are the small pa-
tient number and retrospective design of the study. 
New studies involving more patients are needed to 
analyze the relationship between serum blood ratios 
and PANDO. However, further prospective studies 
are needed.
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